This was the stock's second consecutive day of losses.

This was the stock's third consecutive day of losses.

AbbVie Inc (ABBV) stock saw a decline, ending the day at $178.5 which represents a decrease of $-1.03 or -0.57% from the prior close of $179.53. The stock opened at $179.2 and touched a low of $176.18 ...

Investment analysts at Leerink Partnrs dropped their FY2024 EPS estimates for AbbVie in a research note issued to investors ...

In a regulatory filing, AbbVie (ABBV) stated, “On January 9, 2025, AbbVie determined that it will record an impairment charge related to the ...

If you want to know who really controls AbbVie Inc. ( NYSE:ABBV ), then you'll have to look at the makeup of its share ...

Stock analysts at Leerink Partnrs issued their FY2029 EPS estimates for AbbVie in a research report issued on Monday, January ...

DCF analysis, a reliable and data-driven approach to estimating its intrinsic value. Instead of using future free cash flow ...

AbbVie Inc (ABBV) stock saw a decline, ending the day at $179.53 which represents a decrease of $-0.57 or -0.32% from the prior close of $180.1. The stock opened at $179.63 and touched a low of ...

AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on January 6. Analyst David Risinger ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Vysis, Inc., a leading genomic disease management ... Abbott created the Established Pharmaceuticals Division in 2010. The creation of AbbVie In 2011, Abbott announced it was to separate into ...